The change in Fibrosis-4 index in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide: A retrospective observational study.

Hiroyuki ItoRyota SomeyaShigenori AndoRie ArakiEmiko TsugamiSuzuko MatsumotoHideyuki InoueShinichi AntokuTomoko YamasakiToshiko MoriMichiko Togane

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)

Fixed-ratio combination therapy using IDegLira for the treatment of type 2 diabetes is useful for glycemic control and weight management. In particular, IDegLira may be more effective for lowering FIB-4 than adding unused oral antidiabetic agents or increasing the dose of insulin in GLP-1RA-naïve patients.

Keyphrases

combination therapy
glycemic control
type diabetes
end stage renal disease
weight loss
newly diagnosed
blood glucose
ejection fraction
chronic kidney disease
insulin resistance
rheumatoid arthritis
prognostic factors
peritoneal dialysis
metabolic syndrome
skeletal muscle
disease activity
replacement therapy